Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management

Abstract

Over the past decade, targeted therapies such as BRAF inhibitors, MEK inhibitors and immunotherapies such as anti-CTLA4 and anti-PD1 antibodies have emerged as novel treatments of advanced melanoma. Along with increased use of these therapies, a range of cutaneous adverse events have also emerged, varying from more serious and frequent cutaneous squamous cell carcinoma to mere cosmetic changes such as curly hair or rare severe toxic epidermal necrolysis. Early detection and management of these cutaneous adverse events will aid patients to receive accurate treatment, avoid unnecessary discontinuation of anti-tumour treatment and improve the patient's overall quality of life. This review will describe various cutaneous adverse events of anti-melanoma therapies and its management.

Keywords: Anti-CTLA4; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-PD1; Anti-Programmed cell death-1; B-Raf inhibitors; Cutaneous adverse event; Efecto cutáneo adverso; Inhibidores de BRAF; Inhibidores de MEK; Melanoma metastásico; Metastatic melanoma; Mitogen-activated protein kinase inhibitor.